1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Nexus AG

Nexus AG

NXU.DE
Nexus AGDE flagDeutsche Börse
71.20
EUR
-0.10
- -
1.23BMarket Cap
Nexus AG
NXU.DE
(Deutsche Börse)

Recent

price

71.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
2.93
3.22
3.77
4.33
4.86
5.32
6.23
6.81
7.58
8.67
9.39
10.35
11.95
13.11
14
15.15
15.93
Revenue per Share
0.15
0.25
0.33
0.42
0.48
0.55
0.49
0.52
0.63
0.69
0.69
0.95
1.09
1.21
1.39
1.79
1.98
Basic EPS, GAAP
0.12
0.64
-0.06
0.19
0.35
0.36
0.57
0.39
0.86
0.8
1.19
1.63
1.64
1.77
1.21
2.38
2.99
Free Cash Flow per Basic Share
- -
- -
- -
0.1
0.11
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.19
0.2
0.21
0.22
- -
Dividend per Share
1.11
1.04
2.68
2.97
3.16
3.59
3.86
4.21
4.69
5.01
5.53
6.19
7.09
8.11
8.65
10.18
10.88
Book Value per Share
1.36
1.65
1.41
1.34
1.54
1.32
0.89
0.74
1.14
-0.19
0.16
-0.49
-0.41
5
2.72
3.89
4.77
Tangible Book Value per Share
14
14
14
14
15
15
16
16
16
16
16
16
16
16
17
17
17
Basic Weighted Avg Shares
40
45
54
62
73
80
97
107
119
136
148
163
188
209
241
261
275
Sales/Revenue/Turnover
5.38
8.32
5.92
9.61
9.36
10.3
9.24
10.34
11.28
11.23
9.21
10.41
12.74
13.17
13.19
14.69
15.93
Operating Margin (%)
5
6
7
6
7
7
9
10
10
- -
17
17
17
17
19
19
19
Depreciation Expense
2
4
5
6
7
8
8
8
10
11
11
15
17
19
24
31
34
Net Income, GAAP
5.78
- -
- -
1.05
- -
1.64
19.09
21.06
23.54
26.34
28.12
22.97
24.27
27.48
27.89
22.17
24.66
Effective Tax Rate (%)
5.21
7.89
8.73
9.78
9.86
10.33
7.8
7.61
8.26
8
7.34
9.15
9.12
9.25
9.95
11.79
12.46
Profit Margin (%)
16
22
20
24
26
24
22
21
28
20
22
10
6
94
81
99
117
Working Capital
- -
- -
2
- -
- -
- -
- -
- -
- -
- -
7
9
12
14
15
16
15
LT Debt
47
53
58
68
71
76
89
96
103
108
115
124
142
239
259
283
297
Total Equity
4.2
- -
- -
9.12
- -
10.6
8.38
9.02
9.99
10.32
8.14
9.9
12.02
9.3
8.19
9.72
10.75
Return on Invested Capital (%)
14.5
- -
- -
15.55
- -
16.93
13.14
12.2
13.58
14.23
10.96
13.92
14.35
13.86
15.79
17.33
18.13
Return on Capital (%)
14.96
23.77
17.77
15.06
15.97
16.28
13.25
12.86
14.04
14.31
13.07
16.17
16.4
16.05
17.26
18.97
19.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
16
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
1,194
1,207
1,240

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
189
230
223
Cash, Cash Equivalents & STI
117
152
144
Accounts Receivable, Net
47
46
45
Inventories
5
5
5
Total Current Liabilities
90
119
105
Payables & Accruals
- -
- -
- -
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.2%
21.6%
9.43%
Free Cash Flow
31.44%
23.5%
96.43%
Net Income, GAAP
14.79%
23.56%
28.23%
Sales/Revenue/Turnover
12.62%
12.14%
8.28%
Total Cash Common Dividend
7.75%
7.32%
4.92%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
55
57
59
70
241
2024
63
65
63
71
261
2025
70
71
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.33
0.3
0.39
- -
1.39
2024
0.38
0.34
0.46
- -
1.79
2025
0.48
0.44
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.21
2024
- -
- -
- -
- -
0.22
2025
- -
- -
- -
- -
- -
Similar Companies
Computer Programs and Systems, Inc. (CPSI)
Phreesia, Inc. (PHR)
HeartBeam, Inc. (BEATW)
Cannabis Sativa, Inc. (CBDS)
Dogecoin Cash, Inc. (DOGP)
Caduceus Software Systems Corp. (CSOC)
Business
Nexus AG Nexus AG develops and sells software and hardware solutions along with IT services primarily for healthcare providers including hospitals, clinics, psychiatric institutions, rehabilitation facilities, laboratories, diagnostic centers, radiology departments, senior care homes, and outpatient services; its core offerings encompass the hospital information system NEXUS / HIS or KIS NG for clinical process management with integration of specialized applications, NEXUS / LAB for laboratory diagnostics encompassing pathology, cytology, genetics, central and specialized labs plus communication portals and hardware like cassette and slide printers, radiology solutions including advanced radiology information systems, modular PACS, teleradiology links, and next-generation Vendor Neutral Archives, NEXUS / PSYCHIATRY for psychiatric wards, NEXUS / REHAB and ITR for rehabilitation and residential institutions, NEXUS / HOME and Asebis for homecare and nursing homes, quality management via NEXUS / QM, interface management through NEXUS / INTEGRATION SERVER, archiving and process systems like NEXUS / ARCHIVE and PEGASOS, cloud outsourcing with NEXUS / CLOUD IT, ophthalmology software including ifa systems and Sophrona, interdisciplinary diagnostics via NEXUS / DIS, medical specialist tools like Clinic WinData and DIAGNOSTICS, administrative systems such as NEXUS / PAT and osoTEC, and additional solutions including SINAPSI, highsystemNET, CREATIV OM, SEXTANT, Emed, NEXUS / EPD, NEXUS / AEMP, NEXUS / SPM, EuroSDS, RVS Software, NEXUS / VITA, TESIS VITA, and NEXUS / ESKULAP. Founded in 1989 and headquartered in Donaueschingen, Germany, the company operates through Healthcare Software and Healthcare Services segments, serving customers in Germany, Switzerland, Liechtenstein, the Netherlands, Poland, France, Austria, and other regions across Europe with sites in nine countries and support in 71 more via dealers, targeting somatic hospitals, psychiatric and rehab facilities, labs, radiology, and social institutions with interoperable, process-oriented digital platforms enhanced by AI, voice control, structured terminology, and cloud technologies. In late 2024, Nexus AG entered a strategic investment agreement with TA Associates leading to a voluntary public takeover offer at EUR 70.00 per share announced on November 5, which completed successfully on January 3, 2025, with 94.95% acceptance by shareholders including irrevocable commitments from management, supervisory board, Luxempart, and others, enabling delisting from the Frankfurt Stock Exchange post-settlement in Q1 2025 to provide financial flexibility for R&D in cloud and AI, strategic acquisitions, regional expansions, and accelerated growth away from public market pressures while retaining headquarters, locations, and management.